CTLA4 and Autoimmunity: The remaining patients may develop severe multiorgan autoimmunity requiring lifelong immunosuppressive treatment with Treg-sparing immunosuppression [mammalian target of rapamycin (mTOR) inhibitors] or targeted soluble CTLA-4-Ig (abatacept, belatacept) (10, 11).